Avadel Pharma

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its products include Bloxiverz, Vazculep, Nouress, and Akovaz. It focuses on the approval of FT218, a formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Avadel Pharma reports robust Q3 revenue, eyes market expansion

Avadel Pharma's Q3 performance showed solid revenue and positive EBITDA, with strong patient demand for LUMRYZ.
Despite legal challenges and competition, opportunities exist in market expansion and new patient segments.
The company's focus on persistency, market growth, and product efficacy positions it for future success.
Maintaining strong payer coverage and cash flow positivity are key priorities for upcoming quarters.

Avadel Pharma posts robust Q4 results, eyes strong 2025 growth

Avadel Pharma's strong Q4 performance and focus on LUMRYZ's success position them for revenue growth in 2025 While facing legal challenges, the company's market expansion and revenue targets offer growth potential Investments in persistency rates and new prescribers underscore Avadel's commitment to long-term growth

Avadel Pharma excels in Q1 with revenue surge and legal actions

Avadel Pharma delivered a strong Q1 performance with impressive revenue growth, expanded patient base, and strategic investments in sales and support infrastructure. While facing legal challenges and potential tariff impacts, the company remains confident in its ability to drive long-term success through innovation and market expansion.

Avadel Pharma reports robust Q2 results and pursues growth opportunities

Avadel Pharma's Q2 performance reflects strong revenue growth and profitability milestones, supported by strategic investments in product innovation and market expansion. While facing legal challenges and cost pressures, the company's focus on patient-centric initiatives and revenue guidance raise optimism for sustained growth. Opportunities in new therapeutic areas and portfolio expansion position Avadel Pharma for continued success, contingent on effective execution and competitive positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.